Loading...
Loading...
ONTX| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 8.6M |
| Operating I/L | 12.3M |
| Other Income/Expense | -0.0M |
| Interest Income | 0.0M |
| Pretax | 12.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -8.5M |
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative cancer treatments. The company's primary focus is on two clinical-stage programs: narazaciclib, a multi-targeted kinase inhibitor in Phase I study for solid tumors and hematological malignancies; and oral rigosertib, in Phase I/IIa for the treatment of K-Ras mutated non-small cell lung cancer. Additionally, Onconova is developing a Phase Ib/II ISS with rigosertib monotherapy for advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa, and has a preclinical program for IV/oral rigosertib for COVID-19.
